Company intelligence
Photocure
The Bladder Cancer Company
About Photocure
About Photocure Photocure is a commercial diagnostic company with global reach, committed to driving progress in uro-oncology precision diagnostics, delivering meaningful advances for patients with urological cancers. Our unique core technology has led to better health outcomes for patients worldwide. The company aims to provide an array of transformative solutions that help physicians with timely diagnostic information, to inform more personalized decisions on how best to manage each individual patient. Photocure is headquartered in Oslo, Norway and listed on the Oslo Stock Exchange (OSE: PHO). For more information, please visit www.photocure.com/news On this account Photocure posts about uro-oncology and company activity. All information presented on this account is for informational purposes only and is not intended as a substitute for informed medical advice or recommendations from healthcare professionals. Please consult a healthcare professional for more information about your condition and medicinal products.
Verified activity
Signals from Photocure
3 published signals
Presence & Recognition
Photocure is attending the 78th Congress of the German Society of Urology in Düsseldorf from September 16-19, 2026.
Reported by Photocure
Presence & Recognition
Photocure's CEO Dan Schneider participated in the Pareto Securities Healthcare Conference panel discussing AI strategy, US pricing reform, commercialization, regulatory developments, and FDA processes.
Reported by Photocure
Presence & Recognition
Photocure team will be presenting at the upcoming Pareto Securities Healthcare Conference on September 2 in Stockholm.
Reported by Photocure